NCT00092664已完成3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,104
- 主要终点
- Plasma LDL-C.
研究概览
简要总结
The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High cholesterol
排除标准
- •Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.
结局指标
主要结局
Plasma LDL-C.
次要结局
- Plasma TG and HDL-C; proportion of patients achieving LDL-C targets; tolerability.
研究者
相似试验
已完成
3 期
A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)HypercholesterolemiaNCT00092651Organon and Co1,398
已完成
2 期
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With HypercholesterolemiaHypercholesterolemiaNCT04784442Otsuka Pharmaceutical Co., Ltd.188
终止
3 期
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With HypercholesterolemiaHypercholesterolemiaNCT00532558Takeda657
已完成
2 期
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin IntoleranceHypercholesterolemiaNCT01751984Esperion Therapeutics, Inc.56
终止
2 期
Efficacy of Lapaquistat Acetate in Subjects With HypercholesterolemiaHypercholesterolemiaNCT00865228Takeda224